Project Grant R01DA062278
Award Date
4/15/25
Completion Date
1/30/30
Dollars Obligated
$715K
Federal Agency
National Institute on Drug Abuse
Federal Grant Program
93.279
Assistance Type
Project Grant
Place of Performance
California, USA
Similar Awards
This federal Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $777,398 to Trustees of Boston University's medical campus to investigate the molecular mechanisms linking HIV infection and opioid use disorder that drive neuroinflammation and HIV-associated neurocognitive disorders (HAND). The key focus of the research is to use primary human iPSC-derived microglia cultures to study how HIV infection and...
This $3,472,327 federal Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), aims to study the impact of poly-substance use on the crosstalk between microglia, astrocytes, and neurons that regulates HIV latency. Led by Case Western Reserve University, the project will utilize newly developed methods to derive authentic microglia, astrocytes, and neurons from induced pluripotent stem cells (iPSCs) to investigate...
This $708,397 Project Grant awarded by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) supports research on the role of inflammasomes in opioid-induced pain in the context of HIV. The research aims to construct a cell atlas of opioid-targeted inflammasomes in the spinal cord of HIV pain models, elucidate the role of Wnt5a signaling in establishing inflammasome cell maps, and determine the contribution of glial-specific NLRP3 to...
This $2,426,074 federal Project Grant award from the National Institute on Drug Abuse (NIDA) under CFDA 93.279 - Drug Use and Addiction Research Programs will support research to compare the effects of different medications for opioid use disorder (MOUD) on inflammation and neurocognition in people living with HIV. The research, led by Yale University, aims to evaluate how opioid agonist versus antagonist MOUD treatments impact inflammation and epigenetic changes in the central nervous system of...
This Project Grant award, with a total funding of $234,000.00, was provided by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279). The grant aims to understand the effect of opioids on HIV infection and the reactivation of latent viral reservoirs in the brain. Specifically, the grant will utilize a novel dual fluorescent and bioluminescent HIV virus, called EcoHIV NL4-3 Dual Red, to visualize and measure the impact of opioids, including...
This $751,043 federal Project Grant award from the National Institute on Drug Abuse (CFDA 93.279 - Drug Use and Addiction Research Programs) aims to investigate the cellular and molecular mechanisms underlying the co-occurrence of opioid use disorder (OUD), major depressive disorder (MDD), and HIV in human brain tissue. The grant supports a multi-year research project that will utilize single-cell sequencing approaches to analyze transcriptional and chromatin accessibility changes in the...
This $1,537,749 Project Grant awarded by the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), aims to investigate the molecular mechanisms underlying HIV and methamphetamine-induced neuroinflammation mediated by the astrocyte-specific NLRP6 inflammasome. The research, conducted at the University of Nebraska Medical Center (UNMC), uses in vitro, ex vivo, and in vivo approaches to elucidate how exposure to HIV Tat protein and...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $3,717,777 in funding to the Icahn School of Medicine at Mount Sinai to investigate the impact of nicotine and HIV-1 infection on neuroinflammation and cognitive decline. The research aims to elucidate the role of the NLRP3 inflammasome in HIV-1-associated inflammation, with the goal of identifying potential therapeutic targets to address cognitive...
This federal Project Grant award, valued at $5,147,311 and issued by the National Institute on Drug Abuse (NIDA, CFDA 93.279 - Drug Use and Addiction Research Programs), supports research to investigate the impact of HIV infection and cocaine use on the integrity of the blood-brain barrier (BBB) in people living with HIV (PLWH). The key objectives are to: 1) Determine how immune cell phenotypes and HIV proviral DNA burden in monocytes and T cells contribute to BBB permeability in PLWH with and...
This Project Grant award of $983,672.00, awarded by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279), aims to provide unparalleled insight into the nature and extent of HIV and methamphetamine use in the brain, as well as the host-immune factors that facilitate inflammation and brain injury. The key products and services to be delivered under this award include the development and implementation of innovative single-cell...